Lin, Y.-S.; Cheng, W.-L.; Chang, J.-C.; Lin, T.-T.; Chao, Y.-C.; Liu, C.-S.
IGF-1 as a Potential Therapy for Spinocerebellar Ataxia Type 3. Biomedicines 2022, 10, 505.
https://doi.org/10.3390/biomedicines10020505
AMA Style
Lin Y-S, Cheng W-L, Chang J-C, Lin T-T, Chao Y-C, Liu C-S.
IGF-1 as a Potential Therapy for Spinocerebellar Ataxia Type 3. Biomedicines. 2022; 10(2):505.
https://doi.org/10.3390/biomedicines10020505
Chicago/Turabian Style
Lin, Yong-Shiou, Wen-Ling Cheng, Jui-Chih Chang, Ta-Tsung Lin, Yi-Chun Chao, and Chin-San Liu.
2022. "IGF-1 as a Potential Therapy for Spinocerebellar Ataxia Type 3" Biomedicines 10, no. 2: 505.
https://doi.org/10.3390/biomedicines10020505
APA Style
Lin, Y. -S., Cheng, W. -L., Chang, J. -C., Lin, T. -T., Chao, Y. -C., & Liu, C. -S.
(2022). IGF-1 as a Potential Therapy for Spinocerebellar Ataxia Type 3. Biomedicines, 10(2), 505.
https://doi.org/10.3390/biomedicines10020505